SPRO
Spero Therapeutics, Inc.
Biotechnology · Healthcare · United States
1.06
close · 2026-10-30
value
52
cheaper than peers52
quality
97
stronger fundamentals97
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 2 years ago | 40.6% | 99 |
| earnings yield, latest year | 14.2% | 95 |
| price to sales | 1.31× | 94 |
| price to book | 1.39× | 80 |
| cash flow yield, 3 years ago | -12.5% | 39 |
| cash flow yield, latest year | -20.5% | 35 |
| cash flow yield, 1 year ago | -38.0% | 22 |
| cash flow yield, 2 years ago | -53.5% | 18 |
| earnings yield, 3 years ago | -116.0% | 15 |
| earnings yield, 1 year ago | -119.8% | 12 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 19.2% | 86 |
| operating margin | 14.1% | 84 |
| debt to equity | 4.6% | 74 |
3 of 4 measures available
Facts
| market cap | $62M |
| free cash flow | $28.8M |
| employees | 25 |
| first trade | 2017-11-02 |
| next earnings | 2026-08-12 |
| fundamentals updated | 2026-08-31 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 0.15 | -1.27 | 0.43 | -1.23 |
| free cash flow | -$12.6M | -$23.4M | -$33.0M | -$7.7M |
| net income | $8.6M | -$68.6M | $22.8M | -$46.4M |
| revenue | $59.6M | $27.4M | $96.7M | $48.6M |
| unusual items | -$845,000 | -$877,000 | -$5.3M | -$10.7M |